ProAssurance (NYSE:PRA) Rating Increased to Strong-Buy at Zacks Research

Key Points

• Zacks Research upgraded ProAssurance from a "hold" to a "strong-buy" rating, indicating increased confidence in the company's future performance.
• ProAssurance reported Q2 earnings of $0.52 per share, significantly exceeding analyst estimates of $0.19, despite a 19.9% decrease in year-over-year revenue.
• Large institutional investors increased their stakes in ProAssurance, with notable increases from Deutsche Bank and GAMMA Investing LLC, showcasing growing confidence among major shareholders.

ProAssurance (NYSE:PRA - Get Free Report) was upgraded by research analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a research report issued on Monday,Zacks.com reports. Zacks Research also issued estimates for ProAssurance's FY2025 earnings at $1.18 EPS, Q2 2026 earnings at $0.28 EPS, FY2026 earnings at $1.07 EPS and FY2027 earnings at $1.26 EPS.

ProAssurance Price Performance

Shares of NYSE PRA opened at $23.87 on Monday. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.26 and a quick ratio of 0.26. The company has a market cap of $1.23 billion, a PE ratio of 25.39 and a beta of 0.12. The stock has a fifty day moving average price of $23.83 and a 200 day moving average price of $22.97. ProAssurance has a 1-year low of $13.00 and a 1-year high of $24.14.

ProAssurance (NYSE:PRA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The insurance provider reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.33. The company had revenue of $271.94 million during the quarter, compared to the consensus estimate of $266.72 million. ProAssurance had a net margin of 4.33% and a return on equity of 5.62%. ProAssurance's quarterly revenue was down 19.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.23 EPS. Sell-side analysts forecast that ProAssurance will post 0.8 EPS for the current year.

Hedge Funds Weigh In On ProAssurance

Large investors have recently modified their holdings of the business. Deutsche Bank AG lifted its holdings in shares of ProAssurance by 50.1% in the 4th quarter. Deutsche Bank AG now owns 47,679 shares of the insurance provider's stock valued at $759,000 after buying an additional 15,921 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in ProAssurance by 4.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,991 shares of the insurance provider's stock worth $461,000 after acquiring an additional 1,127 shares in the last quarter. ProShare Advisors LLC lifted its holdings in ProAssurance by 44.4% in the fourth quarter. ProShare Advisors LLC now owns 15,354 shares of the insurance provider's stock valued at $244,000 after acquiring an additional 4,723 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of ProAssurance by 10.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 157,977 shares of the insurance provider's stock worth $2,513,000 after purchasing an additional 15,542 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of ProAssurance by 9,409.8% during the 1st quarter. GAMMA Investing LLC now owns 48,405 shares of the insurance provider's stock worth $1,130,000 after purchasing an additional 47,896 shares in the last quarter. 85.58% of the stock is owned by hedge funds and other institutional investors.

ProAssurance Company Profile

ProAssurance Corporation, through its subsidiaries, provides property and casualty insurance, and reinsurance products in the United States. The company operates through Specialty Property and Casualty, Workers' Compensation Insurance, and Segregated Portfolio Cell Reinsurance segments. It offers professional liability insurance to healthcare providers and institutions, and attorneys and their firms; medical technology liability insurance to medical technology and life sciences companies; and custom alternative risk solutions, including assumed reinsurance, loss portfolio transfers, and captive cell programs for healthcare professional liability insureds.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.